
Unique Value Creation Model
Discover Our Model
Global
Partnerships
Value Realization
Clinical validation
Global out-licensing deals
Innovation
R&D Engine
Competitive advantages in immuno-oncology
Globally competitive pipeline in 3 generations
Our Proven Value Creation Model Is
Enabled by Differentiated Global Capabilities
Deep Immunology Expertise
- Led by principal scientists with decades of research and drug discovery expertise in pharma R&D
- Extensive research in immune regulatory pathways
- 200+ publications by in-house experts in high-impact scientific journals
- 12 novel drug molecules advanced into the clinic since 2016
Global Clinical Development
- Led by world-renowned oncologists with global clinical and drug development expertise in hematology and solid tumors
- Excellent track record in developing innovative oncology drugs
- 300+ medical science publications by in-house experts in high-impact journals
- 14 trials conducted in China, 8 trials conducted in the US, involving more than 1,000 patients worldwide by I-Mab
Shanghai – Global HQ
- Global corporate operations
- Discovery powerhouse
- Clinical operations in multiple sites across China
Maryland – Global HQ
- Global clinical development
- Clinical operations in multiple sites across the U.S.
Other Locations
- Beijing – Clinical operations and regulatory
- Guangzhou – Clinical operations
- I-Mab Hangzhou – GMP manufacturing facility
- Lishui – GSP company
- Hong Kong – Capital market
- San Diego – Translational medicine
Global Partnerships
- > 15 deals
- ~ $1.5B total deal value
- Including the landmark deal with AbbVie
Commercial Partnerships
- > 5 deals
- ~ $345M total deal value
- Including the landmark deal with Jumpcan
Our business is powered by our diverse and experienced global talents
-
70%
R&D Personnel
-
70%
Female Employees
-
61%
Global Experience
-
60%
Advanced Degrees